-
Something wrong with this record ?
ARB a diastolická funkce
[Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial]
Solomon SD, et al.
Language Czech Country Czech Republic
- MeSH
- Antihypertensive Agents pharmacology adverse effects therapeutic use MeSH
- Angiotensin II Type 1 Receptor Blockers pharmacology adverse effects therapeutic use MeSH
- Double-Blind Method MeSH
- Echocardiography MeSH
- Hypertension drug therapy complications MeSH
- Hypertrophy, Left Ventricular etiology prevention & control MeSH
- Blood Pressure radiation effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Renin-Angiotensin System drug effects MeSH
- Aged MeSH
- Heart Rate drug effects MeSH
- Stroke Volume drug effects MeSH
- Tetrazoles pharmacology adverse effects therapeutic use MeSH
- Valine analogs & derivatives pharmacology therapeutic use drug effects MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
Diastolic dysfunction might represent an important pathophysiological intermediate between hypertension and heart failure. Our aim was to determine whether inhibitors of the renin-angiotensin-aldosterone system, which can reduce ventricular hypertrophy and myocardial fibrosis, can improve diastolic function to a greater extent than can other antihypertensive agents. METHODS: Patients with hypertension and evidence of diastolic dysfunction were randomly assigned to receive either the angiotensin receptor blocker valsartan (titrated to 320 mg once daily) or matched placebo. Patients in both groups also received concomitant antihypertensive agents that did not inhibit the renin-angiotensin system to reach targets of under 135 mm Hg systolic blood pressure and under 80 mm Hg diastolic blood pressure. The primary endpoint was change in diastolic relaxation velocity between baseline and 38 weeks as determined by tissue doppler imaging. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00170924. FINDINGS: 186 patients were randomly assigned to receive valsartan; 198 were randomly assigned to receive placebo. 43 patients were lost to follow-up or discontinued the assigned intervention. Over 38 weeks, there was a 12.8 (SD 17.2)/7.1 (9.9) mm Hg reduction in blood pressure in the valsartan group and a 9.7 (17.0)/5.5 (10.2) mm Hg reduction in the placebo group. The difference in blood pressure reduction between the two groups was not significant. Diastolic relaxation velocity increased by 0.60 (SD 1.4) cm/s from baseline in the valsartan group (p<0.0001) and 0.44 (1.4) cm/s from baseline in the placebo group (p<0.0001) by week 38. However, there was no significant difference in the change in diastolic relaxation velocity between the groups (p=0.29). INTERPRETATION: Lowering blood pressure improves diastolic function irrespective of the type of antihypertensive agent used.
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial
- 000
- 04341naa 2200481 a 4500
- 001
- bmc07506121
- 003
- CZ-PrNML
- 005
- 20191213094342.0
- 008
- 080630s2007 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Solomon, Scott D. $7 xx0243096
- 245 10
- $a ARB a diastolická funkce / $c Solomon SD, et al.
- 246 11
- $a Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial
- 314 __
- $a Cardiovascular Division, Brigham and Women's Hospital, Boston
- 520 9_
- $a Diastolic dysfunction might represent an important pathophysiological intermediate between hypertension and heart failure. Our aim was to determine whether inhibitors of the renin-angiotensin-aldosterone system, which can reduce ventricular hypertrophy and myocardial fibrosis, can improve diastolic function to a greater extent than can other antihypertensive agents. METHODS: Patients with hypertension and evidence of diastolic dysfunction were randomly assigned to receive either the angiotensin receptor blocker valsartan (titrated to 320 mg once daily) or matched placebo. Patients in both groups also received concomitant antihypertensive agents that did not inhibit the renin-angiotensin system to reach targets of under 135 mm Hg systolic blood pressure and under 80 mm Hg diastolic blood pressure. The primary endpoint was change in diastolic relaxation velocity between baseline and 38 weeks as determined by tissue doppler imaging. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00170924. FINDINGS: 186 patients were randomly assigned to receive valsartan; 198 were randomly assigned to receive placebo. 43 patients were lost to follow-up or discontinued the assigned intervention. Over 38 weeks, there was a 12.8 (SD 17.2)/7.1 (9.9) mm Hg reduction in blood pressure in the valsartan group and a 9.7 (17.0)/5.5 (10.2) mm Hg reduction in the placebo group. The difference in blood pressure reduction between the two groups was not significant. Diastolic relaxation velocity increased by 0.60 (SD 1.4) cm/s from baseline in the valsartan group (p<0.0001) and 0.44 (1.4) cm/s from baseline in the placebo group (p<0.0001) by week 38. However, there was no significant difference in the change in diastolic relaxation velocity between the groups (p=0.29). INTERPRETATION: Lowering blood pressure improves diastolic function irrespective of the type of antihypertensive agent used.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a blokátory receptorů AT1 pro angiotensin II $x farmakologie $x škodlivé účinky $x terapeutické užití $7 D047228
- 650 _2
- $a antihypertenziva $x farmakologie $x škodlivé účinky $x terapeutické užití $7 D000959
- 650 _2
- $a krevní tlak $x účinky záření $7 D001794
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a echokardiografie $7 D004452
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a srdeční frekvence $x účinky léků $7 D006339
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypertenze $x farmakoterapie $x komplikace $7 D006973
- 650 _2
- $a hypertrofie levé komory srdeční $x etiologie $x prevence a kontrola $7 D017379
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a renin-angiotensin systém $x účinky léků $7 D012084
- 650 _2
- $a tepový objem $x účinky léků $7 D013318
- 650 _2
- $a tetrazoly $x farmakologie $x škodlivé účinky $x terapeutické užití $7 D013777
- 650 _2
- $a valin $x analogy a deriváty $x farmakologie $x terapeutické užití $x účinky léků $7 D014633
- 773 0_
- $w MED00012706 $t Clinical cardiology alert $g Roč. 1, č. 5 (2007), s. 37 $x 1213-2586
- 910 __
- $a ABA008 $b B 2242 $c 407 a $y 1 $z 0
- 990 __
- $a 20080630105116 $b ABA008
- 991 __
- $a 20191213094643 $b ABA008
- 999 __
- $a ok $b bmc $g 621745 $s 474178
- BAS __
- $a 3
- BMC __
- $a 2007 $b 1 $c 5 $d 37 $i 1213-2586 $m Clinical Cardiology Alert $x MED00012706
- LZP __
- $a 2008-6/mkme